[go: up one dir, main page]

AR089282A1 - Poliovirus atenuado: pv-1 mono-cre-x - Google Patents

Poliovirus atenuado: pv-1 mono-cre-x

Info

Publication number
AR089282A1
AR089282A1 ARP120104772A ARP120104772A AR089282A1 AR 089282 A1 AR089282 A1 AR 089282A1 AR P120104772 A ARP120104772 A AR P120104772A AR P120104772 A ARP120104772 A AR P120104772A AR 089282 A1 AR089282 A1 AR 089282A1
Authority
AR
Argentina
Prior art keywords
cre
mono
poliovirus
coding region
dimmed
Prior art date
Application number
ARP120104772A
Other languages
English (en)
Inventor
Wimmer Eckard
Cello Jeronimo
Liu Ying
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of AR089282A1 publication Critical patent/AR089282A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C12N2770/32662—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un poliovirus atenuado se produce mediante ingeniería de un elemento de replicación nativo (cre), dentro de la región genomita 5 no traducida (con inactivación del elemento cre nativo ubicado en la región codificante de 2C (mono-crePV), y reemplazando la secuencia de ácido nucleico de una parte o de toda la región codificante de la cápside (P1) con una región codificante de P1 sustituta que tenga una tendencia de pares de codones reducida. El poliovirus atenuado de manera estable es efectivo para vacunas e inmunización. Método de atenuación.
ARP120104772A 2011-12-16 2012-12-17 Poliovirus atenuado: pv-1 mono-cre-x AR089282A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161576706P 2011-12-16 2011-12-16

Publications (1)

Publication Number Publication Date
AR089282A1 true AR089282A1 (es) 2014-08-13

Family

ID=48613234

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104772A AR089282A1 (es) 2011-12-16 2012-12-17 Poliovirus atenuado: pv-1 mono-cre-x

Country Status (11)

Country Link
US (1) US20140356962A1 (es)
EP (1) EP2791326A4 (es)
JP (1) JP2015502158A (es)
KR (1) KR20140105781A (es)
CN (1) CN104204196A (es)
AR (1) AR089282A1 (es)
BR (1) BR112014014654A2 (es)
CA (1) CA2859044A1 (es)
RU (1) RU2014129220A (es)
TW (1) TW201333196A (es)
WO (1) WO2013090795A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190169235A1 (en) * 2015-11-05 2019-06-06 The Research Foundation For The State University Of New York Modified protein encoding sequences having increased rare hexamer content
WO2017184655A1 (en) * 2016-04-18 2017-10-26 University Of Florida Research Foundaiton, Inc. Stable poliovirus variants and uses thereof
JP2020502080A (ja) * 2016-11-30 2020-01-23 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 弱毒ブタインフルエンザワクチン並びにその作製および使用方法
KR20200103020A (ko) * 2017-12-22 2020-09-01 코다제닉스 인코포레이티드 코돈쌍 탈최적화 영역을 가진 재조합 바이러스 및 암 치료를 위한 이의 용도
CA3091508A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6264940B1 (en) * 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
EP3431099B1 (en) * 2007-03-30 2024-01-03 The Research Foundation for The State University of New York Attenuated viruses useful for vaccines
US8066983B2 (en) * 2008-03-14 2011-11-29 The Research Foundation Of State University Of New York Attenuated poliovirus

Also Published As

Publication number Publication date
EP2791326A1 (en) 2014-10-22
TW201333196A (zh) 2013-08-16
RU2014129220A (ru) 2016-02-10
JP2015502158A (ja) 2015-01-22
BR112014014654A2 (pt) 2019-09-24
CA2859044A1 (en) 2013-06-20
KR20140105781A (ko) 2014-09-02
EP2791326A4 (en) 2015-09-02
WO2013090795A1 (en) 2013-06-20
US20140356962A1 (en) 2014-12-04
CN104204196A (zh) 2014-12-10

Similar Documents

Publication Publication Date Title
AR102579A1 (es) Una solución de nicotina en un recipiente, un sistema electrónico que provee vapor y un proceso para estabilizar dicha solución de nicotina
MX373792B (es) Coronavirus.
BR112018000482A2 (pt) ?composição herbicida, utilização da composição, método para o controle da vegetação indesejada e utilização?
MX2019006467A (es) Composiciones y métodos para mejorar la expresión génica.
MX2016005436A (es) Aparatos para calentar material fumable.
CR20180069A (es) Derivados de la sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
GT201600010A (es) Derivaods de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
ES2627330T3 (es) Uso de JAZ5a para mejorar la resistencia a la sequía en una planta
MX384264B (es) Material anisotropico biocompuesto, implantes medicos que lo comprenden y metodos para el tratamiento del mismo
AR089282A1 (es) Poliovirus atenuado: pv-1 mono-cre-x
CL2021003043A1 (es) Método para producir una planta leñosa genéticamente modificada que tiene biomasa y/o densidad de la madera aumentadas (divisional solicitud 201701418)
ECSP17040923A (es) Derivados de glucagón con estabilidad mejorada
AR100050A1 (es) Proceso para acidificación usando formulaciones ácidas retardadas
MX2017007187A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2019005136A (es) Vacuna contra el parvovirus porcino y el virus del sindrome respiratorio reproductivo porcino y metodos de produccion de esta.
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2016014821A (es) Microorganismo y metodo nuevos para la produccion de 1,2-propanodiol basada en acetol reductasa dependiente de nadph y suministro mejorado de nadph.
MX2017008587A (es) Mirna natural para controlar la expresion de gen y uso del mismo.
MX388525B (es) Métodos mejorados para inactivación de enterovirus, composiciones de vacuna con adsorción de adyuvante y reducida en dosis obtenida de los mismos.
MX2016016210A (es) Metodos para el tratamiento de diabetes tipo 1 utilizando anticuerpos antagonistas del receptor de glucagon.
CL2016000730A1 (es) Material micronizado que contiene carbonato alcalinotérreo para regular el ph de un suelo, método para regular el ph del suelo y uso de un material que contiene carbonato alcalinotérreo.
CL2016000746A1 (es) Un método para producir un l-aminoácido usando una bacteria de la familia de las enterobacteriaceae teniendo atenuada la expresión de un gen que codifica un transportador de fosfato
BR112018008045A2 (pt) micro-organismo recombinante que produz l-treonina e um método para produzir l-treonina com o uso do mesmo
CO2017011964A2 (es) Un metodo para producir hcg recombinante
MX2016012276A (es) Virus de sindrome reproductivo y respiratorio porcino (prrsv) que no ocurre de manera natural y metodos para usarlo.

Legal Events

Date Code Title Description
FB Suspension of granting procedure